Immunotherapy: a new paradigm for androgen-refractory prostate cancer.
Loughlin
Kevin R
KR
Brigham and Women's Hospital, Boston, MA, USA.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D019496:Cancer Vaccines